Endothelial dysfunction markers as a therapeutic target for Sildenafil treatment and effects on metabolic control in type 2 diabetes

Expert Opinion on Therapeutic Targets

Volumn 19, Issue 12, 2015, Pages 1617-1622

  Mandosi, Elisabetta ^a   Giannetta, Elisa ^a   Filardi, Tiziana ^a   Lococo, Manuela ^a   Bertolini, Camilla ^a   Fallarino, Mara ^a   Gianfrilli, Daniele ^a   Venneri, Mary Anna ^a   Lenti, Luisa ^a   Lenzi, Andrea ^a   Morano, Susanna ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

P selectin; phosphodiesterase type 5 inhibitors; sildenafil; type 2 diabetes

Indexed keywords

CD11B ANTIGEN; CD18 ANTIGEN; CD31 ANTIGEN; GLUCOSE; HEMOGLOBIN A1C; HOMOCYSTEINE; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PADGEM PROTEIN; SILDENAFIL; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; PHOSPHODIESTERASE V INHIBITOR; VASODILATOR AGENT;

ADULT; ANTIBODY LABELING; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; FLOW CYTOMETRY; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MALE; METABOLIC REGULATION; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT DURATION; AGED; BLOOD; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; HYPERGLYCEMIA; METABOLISM; PATHOLOGY; VASCULAR ENDOTHELIUM;

AGED; BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; INSULIN; LIPIDS; MALE; MIDDLE AGED; P-SELECTIN; PHOSPHODIESTERASE 5 INHIBITORS; SILDENAFIL CITRATE; VASODILATOR AGENTS;

EID: 84950160008     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2015.1066337     Document Type: Article

References (22)

1. Ballantyne CM, Nambi V. Markers of inflammation and their clinical significance. Atheroscler Suppl 2005;6:21-9
2. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74
3. Phé V, Rouprêt M. Erectile dysfunction and diabetes: a review of the current evidence-based medicine and a synthesis of the main available therapies. Diabetes Metab 2012;38(1):1-13
4. Vardi M, Nini A. Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. Cochrane Database Syst Rev 2007(1):CD002187
5. Kanwar M, Agarwal R, Barnes M, et al. Role of phosphodiesterase-5 inhibitors in heart failure: emerging data and concepts. Curr Heart Fail Rep 2013;10(1):26-35
6. Giannetta E, Isidori AM, Galea N, et al. Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. Circulation 2012;125(19):2323-33
7. Giannetta E, Feola T, Gianfrilli D, et al. Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials. BMC Med 2014;12(1):185
8. Santi D, Giannetta E, Isidori AM, et al. Therapy of endocrine disease: effects of chronic use of phosphodiesterase inhibitors on endothelial markers in type 2 diabetes mellitus: a meta-analysis. Eur J Endocrinol 2014
9. Morano S, Mandosi E, Fallarino M, et al. Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebocontrolled study. Eur Urol 2007;52(6):1768-74
10. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26
11. De Meyer GRY, Herman AG. Vascular endothelial dysfunction. Prog Cardiovasc Dis 1997;39:325-42
12. Meyrelles SS, Peotta VA, Pereira TM, Vasquez EC. Endothelial dysfunction in the apolipoprotein E-deficient mouse: insights into the influence of diet, gender and aging. Lipids Health Dis 2011;10:211
13. Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulations. Endothelial dysfunction as a target for prevention of cardiovascular disease. J Am Coll Cardiol 1995;26:1235-41
14. Versari D1, Daghini E, Virdis A, et al. Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care 2009;32(Suppl 2):S314-21
15. Iribarren C. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001;103:2668-73
16. Burnett LA. Serum biomarker measurements of endothelial function and oxidative stress after daily dosing of sildenafil in Type 2 diabetic men with erectile dysfunction. J Urol 2009;181(1):245-51
17. Vestweber D, Blanks JE. Mechanism that regulate the function of selectins and their ligands. Physiol Rev 1999;79(1):181-213
18. Ayala JE, Bracy DP, Julien BM, et al. Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. Diabetes 2007;56(4):1025-33
19. Tooke JE, Goh KL. Endotheliopathy precedes type 2 diabetes. Diabetes Care 1998;21:2047-9
20. Pinkney JH, Stehouwer CD, Coppack SW, Yudkin JS. Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes 1997;46(Suppl 2):S9-S13
21. Sabatini S, Sgrò P, Duranti G, et al. Tadalafil alters energy metabolism in C2C12 skeletal muscle cells. Acta Biochim Pol 2011;58(2):237-41
22. Phillips BG, Kato M, Pesek CA, et al. Sympathetic activation by sildenafil. Circulation 2000;102:3068-73